[go: up one dir, main page]

MX2020013385A - Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion. - Google Patents

Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.

Info

Publication number
MX2020013385A
MX2020013385A MX2020013385A MX2020013385A MX2020013385A MX 2020013385 A MX2020013385 A MX 2020013385A MX 2020013385 A MX2020013385 A MX 2020013385A MX 2020013385 A MX2020013385 A MX 2020013385A MX 2020013385 A MX2020013385 A MX 2020013385A
Authority
MX
Mexico
Prior art keywords
bupropion
methods
modulating
plasma levels
tetrabenazine
Prior art date
Application number
MX2020013385A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of MX2020013385A publication Critical patent/MX2020013385A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta divulgación se refiere a métodos que administran bupropión, como S-bupropión o R-bupropión, junto con tetrabenazina, alfa-dihidrotetrabenazina o beta-dihidrotetrabenazina a un ser humano. También se describen formas de dosificación, sistemas de administración de fármacos y métodos relacionados con tetrabenazina, alfa-dihidrotetrabenazina o beta-dihidrotetrabenazi na y bupropión, como S-bupropión o R-bupropión.
MX2020013385A 2018-06-10 2019-06-10 Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion. MX2020013385A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682998P 2018-06-10 2018-06-10
US201862683399P 2018-06-11 2018-06-11
PCT/US2019/036406 WO2019241162A1 (en) 2018-06-10 2019-06-10 Methods of modulating tetrabenazine metabolites plasma levels using bupropion

Publications (1)

Publication Number Publication Date
MX2020013385A true MX2020013385A (es) 2021-05-27

Family

ID=68843534

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013385A MX2020013385A (es) 2018-06-10 2019-06-10 Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.

Country Status (17)

Country Link
EP (1) EP3790538A4 (es)
JP (2) JP2021529826A (es)
KR (2) KR20210018914A (es)
CN (1) CN112292121A (es)
AU (2) AU2019284477B2 (es)
BR (1) BR112020025064A2 (es)
CA (1) CA3101375A1 (es)
CL (1) CL2020003189A1 (es)
CO (1) CO2021000037A2 (es)
CR (1) CR20200616A (es)
EC (1) ECSP20082568A (es)
IL (1) IL279332A (es)
MX (1) MX2020013385A (es)
NI (1) NI202000095A (es)
PE (1) PE20210370A1 (es)
SG (1) SG11202011762VA (es)
WO (1) WO2019241162A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200345663A1 (en) * 2018-06-10 2020-11-05 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
JP2005510449A (ja) * 2001-02-08 2005-04-21 アンドルックス ファーマスーティカルズ インコーポレーテッド 改良型制御放出経口剤形
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US9707191B2 (en) * 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10105327B2 (en) * 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
PL3265085T3 (pl) * 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
WO2016210180A2 (en) * 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders

Also Published As

Publication number Publication date
KR20210018914A (ko) 2021-02-18
KR20240034871A (ko) 2024-03-14
JP2021529826A (ja) 2021-11-04
CL2020003189A1 (es) 2021-05-28
EP3790538A4 (en) 2021-06-30
CA3101375A1 (en) 2019-12-19
IL279332A (en) 2021-01-31
AU2019284477A1 (en) 2021-01-28
CR20200616A (es) 2021-03-15
BR112020025064A2 (pt) 2021-03-23
ECSP20082568A (es) 2021-02-26
JP2024059744A (ja) 2024-05-01
AU2022268331A1 (en) 2022-12-15
CO2021000037A2 (es) 2021-01-18
AU2022268331B2 (en) 2024-11-14
EP3790538A1 (en) 2021-03-17
PE20210370A1 (es) 2021-02-26
SG11202011762VA (en) 2020-12-30
AU2019284477B2 (en) 2022-08-11
NI202000095A (es) 2021-06-22
CN112292121A (zh) 2021-01-29
WO2019241162A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
EP3572070A4 (en) RETARD ACTIVE SUBSTANCE RELEASE SYSTEM FOR ANALGETIC LOCAL STUNNING AND MANUFACTURING METHOD AND APPLICATION THEREOF
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY187540A (en) Compounds active towards bromodomains
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12022551468A1 (en) Compounds active towards nuclear receptors
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020013385A (es) Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.
IN2013MU03370A (es)
MX2020008129A (es) Composicion farmaceutica que comprende un derivado acilado de un analogo de insulina humana y metodo de preparacion de la misma.
PH12016501347A1 (en) Filters for infusion sets
MY203919A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX2019008847A (es) Profarmacos de cisteamina.
WO2020068020A3 (en) Targeted drug delivery system to be used in treating osteomyelitis
UA104582U (uk) Спосіб лікування неускладненої варикозної хвороби